FG 2216
Alternative Names: FG-2216; YM 311Latest Information Update: 05 Nov 2023
At a glance
- Originator FibroGen
- Developer Astellas Pharma
- Class Amino acids; Antianaemics; Isoquinolines; Small molecules
- Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 01 Jul 2018 Discontinued - Phase-I for Anaemia in Japan (PO) (Astellas pipeline, November 2018)
- 01 Jul 2018 Discontinued - Phase-II for Anaemia in Europe (PO) (Astellas pipeline, November 2018)
- 31 Jan 2018 Discontinued - Phase-II for Anaemia in USA (PO)